Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 12/20 | 0.60 |
| ▸ | LPAR2 | Q9HBW0 | 9/20 | 0.60 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.53 |
| ▸ | PRKCG | P05129 | 2/20 | 0.53 |
| ▸ | PRKCB | P05771 | 2/20 | 0.53 |
| ▸ | PRKCA | P17252 | 2/20 | 0.53 |
| ▸ | PRKCH | P24723 | 2/20 | 0.53 |
| ▸ | PRKCI | P41743 | 2/20 | 0.53 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.53 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.53 |
| ▸ | PRKCZ | Q05513 | 2/20 | 0.53 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.53 |
| ▸ | PRKD1 | Q15139 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18548543 | 1.00 | ENPP2 (0.60) | ENPP2LPAR2PRKD3PRKCGPRKCB | |
| SCHEMBL21518914 | 0.91 | PRKD3 (0.61) | ENPP2LPAR2PRKD3PRKCGPRKCB | |
| SCHEMBL1681846 | 0.91 | PRKD3 (0.61) | ENPP2LPAR2PRKD3PRKCGPRKCB | |
| SCHEMBL3111012 | 0.91 | PRKD3 (0.61) | ENPP2LPAR2PRKD3PRKCGPRKCB | |
| SCHEMBL9873267 | 0.91 | PRKD3 (0.61) | ENPP2LPAR2PRKD3PRKCGPRKCB | |
| SCHEMBL25268261 | 0.91 | PRKD3 (0.61) | ENPP2LPAR2PRKD3PRKCGPRKCB | |
| SCHEMBL22960173 | 0.91 | PRKD3 (0.61) | ENPP2LPAR2PRKD3PRKCGPRKCB | |
| SCHEMBL22960177 | 0.91 | PRKD3 (0.61) | ENPP2LPAR2PRKD3PRKCGPRKCB | |
| SCHEMBL21518916 | 0.91 | PRKD3 (0.61) | ENPP2LPAR2PRKD3PRKCGPRKCB | |
| SCHEMBL16912929 | 0.91 | PRKD3 (0.61) | ENPP2LPAR2PRKD3PRKCGPRKCB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11278559-B2 | Prodrug compounds and their uses | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2022-03-22 | — | — | US | disclosed |
| EP-3623364-A1 | PRODRUG COMPOUNDS AND THEIR USES | Ligand Pharmaceuticals, Inc. (US) | 2020-03-18 | — | — | EP | disclosed |
| US-10449210-B2 | Prodrug compounds and their uses | LIGAND PHARMACEUTICALS INC. (US) | 2019-10-22 | — | — | US | disclosed |
| US-20170056429-A1 | PRODRUG COMPOUNDS AND THEIR USES | Ligand Pharmaceutical, Inc. (US) | 2017-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10449210-B2 | Prodrug compounds and their uses | PYGL, PHYKPL, PCK1 | ENPP2 194/4885LPAR2 1914/4885PRKD3 761/4885 |
| US-11278559-B2 | Prodrug compounds and their uses | PYGL, GLS2, SLC10A1 | ENPP2 88/4885LPAR2 1045/4885PRKD3 2220/4885 |
| US-20170056429-A1 | PRODRUG COMPOUNDS AND THEIR USES | PYGL, PHYKPL, PCK1 | ENPP2 194/4885LPAR2 1914/4885PRKD3 761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.